To determine whether cholesterol lowering reduces coronary heart disease (CHD) incidence or total mortality, whether cholesterol lowering in general is harmful, and whether some types of intervention to reduce cholesterol have negative side-effects.
How were differences between studies investigated?
The difference between the results of studies of different size was emphasised by weighting up the larger studies in the graphical display of the log ORs. Differences in trial design were investigated by examining data from unifactorial and multifactorial trials, and primary and secondary prevention trials, separately.
Secondary analyses were also carried out to examine the effect of cholesterol reduction on total mortality when hormone findings were excluded. More generally, the heterogeneity in cholesterol lowering, which was introduced by including a range of interventions, was controlled by including the degree of reduction in the statistical analyses.
Results of the review
Thirty-five studies in total were included: 31 unifactorial trials, 5 unifactorial primary prevention trials and 26 unifactorial secondary prevention trials. These represented 11 dietary trials, 9 fibrate trials, 4 hormonal trials and 11 'other' trials.
CHD mortality: a reduced risk of CHD was significantly associated with reduction in serum cholesterol in all trials combined (p<0.002), all unifactorial trials (p<0.003) and unifactorial secondary prevention trials (p<0.009), with an estimated 13 to 14% reduction in CHD mortality for every 10% reduction in serum cholesterol. For any given reduction in serum cholesterol, CHD mortality risk was 27% higher with hormonal interventions.
Non-CHD mortality: risk was not related to cholesterol reduction in any of the analyses. Fibrate usage resulted in a 30% increase in risk (p=0.01) for all trials, and also with an increase in risk for unifactorial trials (29% increase, p=0.013) and unifactorial primary prevention trials (39% increase, p=0.005). Hormone use was also associated with an increase in risk (55% increase, p<0.05). The conventional pooled OR estimates indicated a trend towards excess risk in all subsets. This trend was statistically significant for unifactorial trials (19% increase, p<0.05) and for unifactorial primary prevention trials (21% increase, p<0.05).
Total mortality: cholesterol reduction was associated with a reduced risk of mortality in all trials, unifactorial trials and unifactorial secondary prevention trials (all p<0.05). For every 10% reduction in serum cholesterol, mortality risk was reduced by 8 to 10%. Fibrate use was associated with increased total mortality for all trials (17% increase, p=0.02), all unifactorial trials (17% increase, p=0.03) and unifactorial primary prevention trials (35% increase, p<0.02). Hormones were not used in the primary prevention trials included in this analysis, but in all other sets of trials it was associated with increased mortality (32 to 33% increase, p=0.01). The conventional pooled OR analyses did not detect a statistically-significant effect of intervention on total mortality.
